Selegiline as the primary treatment of Parkinson's disease - A long-term double-blind study

Acta Neurologica Scandinavica

Volumn 95, Issue 4, 1997, Pages 211-218

  Myllyla V V ^a   Sotaniemi, K A ^a   Hakulinen, P ^b   Maki Ikola O ^b   Heinonen, E H ^b  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

fluctuations in disability; levodopa; Parkinson's disease; selegiline

Indexed keywords

LEVODOPA; PLACEBO; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HALLUCINATION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0030956709     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1997.tb00101.x     Document Type: Article

References (32)

1. HEINONEN EH, LAMMINTAUSTA R. A review of the pharmacology of selegiline. Acta Neurol Scand 1991: (Suppl 136) 84: 44-59.
2. HEIKKILA RE, MANZINO L, CABBAT FS, DUVOISIN RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984: 311: 467-9.
3. LANGSTON JW, FORNO LS, REBERT CS, IRWIN I. Selective nigral toxicity after administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1994: 292: 390-4.
4. MYLLYLÄ VV, SOTANIEMI KA, TUOMINEN J, HEINONEN EH. Selegiline as primary treatment in early Parkinson's disease - interim report. Acta Neurol Scand 1989: 126: 177-82.
5. MYLLYLÄ VV, SOTANIEMI KA, TUOMINEN J, HEINONEN EH. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992: 42: 339-43.
6. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989: 321: 1364-71.
7. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993: 328: 176-83.
8. TETRUD JW, LANGSTON JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989: 245: 519-22.
9. LANGJSTON JW. Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies. Neurology 1990: 40(Suppl 3): 61-6.
10. SCHULZER M, MAK E, CALNE DB. The antiparkinsonian efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992: 32: 795-8.
11. OLANOW CW, CALNE D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 1992: 42: 13-26.
12. WARD CD. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994: 57: 217-20.
13. BRANNAN T, YAHR MD. Comparative study of selegiline plus 1-dopa-carbidopa versus 1-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995: 37: 95-8.
14. OLANOW CW, KOLLER W. Patients taking selegiline may have received more levodopa than necessary. Brit Med J 1996: 312: 702-3.
15. YU PH, LAI CT. Selegiline may be toxic in presence of increased dopamine concentrations. Brit Med J 1996: 312: 703-4.
16. MYLLYLÄ VV, HEINONEN EH, VUORINEN JA, KILKKU OI, SOTANIEMI KA. Early selegiline reduces levodopa dose requirement in Parkinson's disease. Acta Neurol Scand 1995: 91: 177-82.
17. LARSEN JP, BOAS J and the Norwegian-Danish Parkinson Study Group. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability. An interim analysis of the Norwegian-Danish 5-year study. Mov Dis, in press.
18. PRZUNTEK H. Five years' analysis of the SELEDO study. Abstract P05.127. Neurology 1996: 46: A376.
19. Parkinson's Disease Study Group in the United Kingdom. Comparison of therapeutic effects of levodopa. levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Br Med J 1993: 307: 469-72.
20. LEES AJ and the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Br Med J 1995: 311: 1602-7.
21. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996: 9: 37-45.
22. MÄKI-IKOLA O, KILKKU O, HEINONEN E. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Br Med J 1996: 312: 702.
23. OLANOW CW, HAUSER RA, GAUGER L et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995: 38: 771-7.
24. KUSHLEIKA J, CHECKOWAY H, WOODS JS et al. Selegiline and lymphocyte Superoxide dismutase activities in Parkinson's disease. Ann Neurol 1996: 39: 378-81.
25. KNOLL J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neural Transm 1978: 43: 177-98.
26. FINNEGAN KT, SKRATT JJ, IRWIN I, DELANNEY LE, LANGSTON JW. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol 1990: 184: 119-24.
27. BRONZETTI E, FELICI L, FERRANTE F, VALSECCHI B. Effect of ethylcholine mustard aziridinium (AF64A) and of the monoamine oxidase-B-inhibitor L-deprenyl on the morphology of rat hippocampus. Int J Tissue React 1992: 14: 175-82.
28. AHOLA T, HAAPALINNA A, HEINONEN E, HERVONEN A, SUHONEN J. Protection by L-deprenyl of intact peripheral sympathetic neurons exposed to neurotoxin 6-hydroxydopamine (6-OHDA). 11th International Symposium of Parkinson's disease, Rome, March 26-30, 1994. New trends Clin Neuropharmacol 1994: 7: 287 (abstract).
29. TATTON WG, GREENWOOD CE. Rescue of dying neurons: a new action of deprenyl in MPTP parkinsonism. J Neurosci Res 1991: 30: 666-72.
30. SALO PT, TATTON WG. Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 1992: 31: 394-400.
31. TYTTON WG, SENIUK NA. "Trophic-like" actions of (-)-deprenyl on neurons and astroglia. Acad Biomed Drug Res 1994: 7: 238-48.
32. ANSARI KS, YU PH, KRUCK TPA, TATTON WG. Rescue of axotomized immature rat facial motoneurons by R-(-)-deprenyl: Stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 1993: 13: 4042-53.